MannKind Corporation Earnings: Are Better Times Ahead?

Investors in the biotech company have waited a long time for success, but will it ever come?

May 10, 2014 at 3:15PM

On Monday, MannKind (NASDAQ:MNKD) will release its quarterly report, and investors don't expect any immediate positive results from the clinical-stage biotechnology company. The company has been waiting for a long time for FDA approval of its Afrezza inhaled insulin product, but established insulin producers Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) are working hard to protect their competitive advantage, and it's still unclear whether MannKind will convince the FDA that any safety issues with Afrezza are less substantial than the potential benefits.

Dealing with insulin is a big hassle for patients suffering with diabetes, as the need for injections is at best a chore and at worst can cause complications for diabetics. The promise of an inhalable insulin product is attractive to many diabetes sufferers, and that has driven interest in MannKind for years. Yet investors are impatient for FDA approval to see just how big the opportunity will be for MannKind, especially in light of potential competition. Let's take an early look at what's been happening with MannKind over the past quarter and what we're likely to see in its report.

Dreamboat (2nd generation) inhaler. Source: MannKind.

Stats on MannKind

Analyst EPS Estimate


Year-Ago EPS


Revenue Estimate


Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

Will MannKind earnings ever appear?
With MannKind earning no revenue, analyst earnings projections all hinge on how much they expect the company to spend. Those loss projections have risen recently, with first-quarter loss estimates widening 30% and full-year 2014 loss projections widening by 40%. Yet the stock is up 22% since early February.

MannKind's fourth-quarter financial report didn't hold any big surprises for investors. Operating expenses rose 39%, with the rise coming largely from stock-based compensation charges. Losses per share fell, but only because the number of shares MannKind had outstanding rose dramatically.

The key event for MannKind during the quarter, though, came in April, when an FDA advisory committee recommended that Afrezza be approved, with a unanimous 14-0 vote for type 2 diabetes and by 13-1 for type 1 diabetes. That news was especially welcome because of a scare among investors when the advisory panel presented its briefing materials, which indicated that MannKind had thrown some curveballs at the FDA.

Unfortunately, MannKind investors haven't gotten everything they wanted, as the FDA announced that it would delay its full approval decision beyond its initial April 15 deadline. Yet even though some investors got nervous about the delay, the fact that the deadline fell so close to the date on which the advisory panel made its recommendation is a good reason for the FDA to give itself more time to evaluate briefing materials and make a more considered decision.

One essential aspect of MannKind's future is whether it will find a partner for distributing Afrezza if it gains FDA approval. Because Eli Lilly and Novo Nordisk compete directly against Afrezza with insulin products of their own, MannKind will likely have to look elsewhere for potential partners. Yet with some other major pharmaceutical companies looking to ramp up their exposure to the diabetes space, MannKind should find little trouble gaining interest -- as long as the product gets approved.

In the MannKind earnings report, investors will want to listen for whether the company has made progress in finding a partner. For the most part, though, investors simply have to wait and see what the FDA has to say before MannKind can come up with a strategy for making the most of the Afrezza opportunity.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Click here to add MannKind to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Dan Caplinger and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers